Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
96M
-
Number of holders
-
218
-
Total 13F shares, excl. options
-
61.8M
-
Shares change
-
-468K
-
Total reported value, excl. options
-
$4.48B
-
Value change
-
-$41.8M
-
Put/Call ratio
-
2.14
-
Number of buys
-
117
-
Number of sells
-
-91
-
Price
-
$72.62
Significant Holders of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) as of Q1 2022
260 filings reported holding RARE - Ultragenyx Pharmaceutical Inc. - COMMON STOCK as of Q1 2022.
Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) has 218 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 61.8M shares
of 96M outstanding shares and own 64.35% of the company stock.
Largest 10 shareholders include PRICE T ROWE ASSOCIATES INC /MD/ (11.9M shares), VANGUARD GROUP INC (5.96M shares), FEDERATED HERMES, INC. (3.99M shares), WELLINGTON MANAGEMENT GROUP LLP (3.37M shares), Capital International Investors (3.35M shares), Clearbridge Investments, LLC (2.86M shares), Capital World Investors (2.77M shares), ALKEON CAPITAL MANAGEMENT LLC (2.37M shares), STATE STREET CORP (1.95M shares), and ALLIANCEBERNSTEIN L.P. (1.37M shares).
This table shows the top 218 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.